For instance, under the above considerations, one dose of Trastuzumab in the AC‐TH regimen for the treatment of HER2+ breast cancer costs around $900,144 while the antisense oligonucleotide drug Nusinersen for the treatment of spinal muscular atrophy is prized at $125,000 per injection.143 Therefore, for therapeutic DN to enter clinical trials, significant investments will be required due to the comparatively large costs of small‐scale GMP‐compliant oligonucleotide synthesis. This evidence concerns the gene ERBB2 and breast cancer.